AMPLIA THERAPEUTICS LIMITED - Announcements

2.63%

18.5¢

Market Cap $89.99M

Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ATX	App 4E - Preliminary Final Report YE 31 March 2021	PRICE SENSITIVE	31/05/21	327.33KB	Share
ATX	Proposed issue of Securities - ATX	PRICE SENSITIVE	04/05/21	25.57KB	Share
ATX	Amplia Announces $3.8m Share Placement	PRICE SENSITIVE	04/05/21	113.35KB	Share
ATX	Trading Halt	PRICE SENSITIVE	30/04/21	195.75KB	Share
ATX	Preclinical Data Support Developmnt AMP945 Pancreatic Cancer	PRICE SENSITIVE	28/04/21	181KB	Share
ATX	Quarterly Report and Shareholder Update	PRICE SENSITIVE	28/04/21	2.21MB	Share
ATX	ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH	PRICE SENSITIVE	20/04/21	186.09KB	Share
ATX	Amplia Completes Dosing in Phase 1 Clinical Study of AMP945	PRICE SENSITIVE	15/04/21	103.52KB	Share
ATX	Amplia and Garvan Institute Enter Collaboration Agreement	PRICE SENSITIVE	18/03/21	109.54KB	Share
ATX	Amplia Completes Single Dose Study of AMP945	PRICE SENSITIVE	17/03/21	102.66KB	Share
ATX	Amplia Initiates Multiple Dose Study of AMP945	PRICE SENSITIVE	17/02/21	105.52KB	Share
ATX	Investor Update - February 2021	PRICE SENSITIVE	11/02/21	1.9MB	Share
ATX	Quarterly Activities and Cashflow Reports - Dec 2020 Qtr	PRICE SENSITIVE	28/01/21	246.63KB	Share
ATX	Amplia Receives $0.53m R&D Tax Incentive	PRICE SENSITIVE	02/12/20	104.44KB	Share
ATX	Appendix 4D and Financial Report Half Year Ended 30 Sep 2020	PRICE SENSITIVE	27/11/20	828.49KB	Share
ATX	ATX - Sep 2020 Quarter Activities and Cashflow Reports	PRICE SENSITIVE	29/10/20	165.5KB	Share
ATX	Response to ASX Price Query	PRICE SENSITIVE	20/10/20	205.56KB	Share
ATX	First Human Dose in Phase 1 Clinical Trial of AMP945	PRICE SENSITIVE	08/10/20	105.87KB	Share
ATX	Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial	PRICE SENSITIVE	08/09/20	108KB	Share
ATX	Entitlement Offer Completed	PRICE SENSITIVE	30/07/20	106.98KB	Share
ATX	Quarterly Activities and Cashflow Reports - June 2020	PRICE SENSITIVE	27/07/20	219.1KB	Share
ATX	Nucleus Network Appointed to Conduct Phase 1 Clinical Trial	PRICE SENSITIVE	23/07/20	104.82KB	Share
ATX	Institutional Entitlement Offer Completed	PRICE SENSITIVE	03/07/20	109.29KB	Share
ATX	Capital Raising - Investor Presentation	PRICE SENSITIVE	01/07/20	3.63MB	Share
ATX	Entitlement Offer to Fund Phase 1 Clinical Trial	PRICE SENSITIVE	01/07/20	226.49KB	Share
ATX	Trading Halt	PRICE SENSITIVE	01/07/20	481.97KB	Share
ATX	Pause in Trading	PRICE SENSITIVE	01/07/20	115.53KB	Share
ATX	Preliminary Toxicology Studies Support Phase1 Clinical Trial	PRICE SENSITIVE	30/06/20	105.32KB	Share
ATX	Trading Halt	PRICE SENSITIVE	29/06/20	134.89KB	Share
ATX	Preliminary Final Report - YE 31 March 2020	PRICE SENSITIVE	29/05/20	226.35KB	Share
ATX	FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis	PRICE SENSITIVE	19/05/20	113.17KB	Share
ATX	Quarterly Activities Report - March 2020 Qtr	PRICE SENSITIVE	28/04/20	114.28KB	Share
ATX	App 4C - Quarterly Cash Flow Report - March 2020 Qtr	PRICE SENSITIVE	28/04/20	163.85KB	Share
ATX	FDA Awards Orphan Drug Designation for Pancreatic Cancer	PRICE SENSITIVE	25/03/20	103.05KB	Share
ATX	Dr. John Lambert appointed as Managing Director	PRICE SENSITIVE	06/02/20	100.02KB	Share
ATX	Appendix 4C Cash Flow - Dec 2019 Qtr	PRICE SENSITIVE	30/01/20	179.52KB	Share
ATX	Amplia Therapeutics Undertakes Placement	PRICE SENSITIVE	20/01/20	102.62KB	Share
ATX	Trading Halt	PRICE SENSITIVE	16/01/20	180.43KB	Share
ATX	App 4D - Financial Report Half Year Ended 30 Sep 2019	PRICE SENSITIVE	29/11/19	658.67KB	Share
ATX	App 4C - Sep 2019 Qtr Cash Flows Statement	PRICE SENSITIVE	01/11/19	77.92KB	Share
ATX	Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr	PRICE SENSITIVE	31/07/19	191.95KB	Share
ATX	RightsIssue Participation Supports Clinical-Enabling Studies	PRICE SENSITIVE	31/07/19	106.94KB	Share
ATX	Amplia Therapeutics Reports Lead Candidate Preclinical Data	PRICE SENSITIVE	23/07/19	230.93KB	Share
ATX	Rights Issue Prospectus	PRICE SENSITIVE	28/06/19	350.41KB	Share
ATX	Dr John Lambert appointed as new CEO	PRICE SENSITIVE	24/06/19	116.58KB	Share
ATX	Capital Raising for Clinical-Enabling Studies	PRICE SENSITIVE	12/06/19	104.96KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2019	PRICE SENSITIVE	29/05/19	141.78KB	Share
ATX	Appendix 4C - Quarterly Statement of Cash Flows	PRICE SENSITIVE	30/04/19	162.91KB	Share
ATX	European Patent Completes IP Protection in Major Markets	PRICE SENSITIVE	01/04/19	116.22KB	Share
ATX	Appendix 4C - December 2018 Quarter Cashflow Statement	PRICE SENSITIVE	29/01/19	161.87KB	Share
ATX	App 4D Half Year Accounts 30 Sep 2018	PRICE SENSITIVE	29/11/18	702.6KB	Share
ATX	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	213.29KB	Share
ATX	Response to ASX Query	PRICE SENSITIVE	14/08/18	591.8KB	Share
ATX	Appendix 4C - June 2018 Quarter Cashflow Statement	PRICE SENSITIVE	30/07/18	169.64KB	Share
ATX	European Patent Granted for Innate's Drug Candidate AMP-886	PRICE SENSITIVE	23/07/18	121.4KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2018	PRICE SENSITIVE	31/05/18	756.28KB	Share
ATX	App 4C - March 2018 Quarterly Cash Flow Report	PRICE SENSITIVE	30/04/18	158.74KB	Share
ATX	Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates	PRICE SENSITIVE	23/03/18	224.03KB	Share
ATX	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	09/03/18	201.26KB	Share
ATX	Appendix 4C - December 2017 Quarter	PRICE SENSITIVE	31/01/18	648.21KB	Share
ATX	Half Yearly Report and Accounts - HY ending 30 Sep 2017	PRICE SENSITIVE	30/11/17	1.22MB	Share
ATX	Appendix 4C - September 2017 Quarter Cashflows	PRICE SENSITIVE	30/10/17	650.42KB	Share
ATX	Corporate Update	PRICE SENSITIVE	20/10/17	480.31KB	Share
ATX	App 4C - Quarterly Statement of Cashflows - June 2017 Qtr	PRICE SENSITIVE	28/07/17	647.2KB	Share
ATX	No Change in Trial Outcome Following Additional Analysis	PRICE SENSITIVE	21/07/17	500.52KB	Share
ATX	Response to ASX Price Query	PRICE SENSITIVE	11/07/17	169.59KB	Share
ATX	Top-Line Results for Trial of MIS416	PRICE SENSITIVE	27/06/17	528.48KB	Share
ATX	Trading Halt	PRICE SENSITIVE	23/06/17	326.24KB	Share
ATX	FDA Clearance - MIS416 Investigational New Drug Application	PRICE SENSITIVE	21/06/17	368.33KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2017	PRICE SENSITIVE	31/05/17	252.45KB	Share
ATX	Appendix 4C - March 17 Quarter Statement of Cash Flows	PRICE SENSITIVE	28/04/17	655.95KB	Share
ATX	Completion of Phase 2B Trial of MIS416	PRICE SENSITIVE	20/04/17	383.67KB	Share
ATX	Private Placement to raise Additional Working Capital	PRICE SENSITIVE	17/03/17	392.4KB	Share
ATX	Trading Halt	PRICE SENSITIVE	16/03/17	618.44KB	Share
ATX	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
ATX	Phase 2B Trial of MIS416 on Schedule to Complete April 2017	PRICE SENSITIVE	28/02/17	372.37KB	Share
ATX	TOV: IIL Panel Declines to Conduct Proceedings	PRICE SENSITIVE	20/02/17	73.18KB	Share
ATX	Appendix 4C - Dec 2016 Quarter Statement of Cashflows	PRICE SENSITIVE	31/01/17	654.86KB	Share
ATX	Response to ASX Price Query	PRICE SENSITIVE	27/01/17	773.02KB	Share
ATX	Response to Price Query	PRICE SENSITIVE	30/12/16	504.92KB	Share
ATX	App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16	PRICE SENSITIVE	29/11/16	531.05KB	Share
ATX	Phase 2B Update - Patients Wanting Access to Drug Post Trial	PRICE SENSITIVE	07/11/16	370.49KB	Share
ATX	Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr-IIL.AX	PRICE SENSITIVE	31/10/16	668.82KB	Share
ATX	Clinical Trials Update - 2016 Bioshares Biotech Summit-IIL.AX	PRICE SENSITIVE	02/08/16	1013.24KB	Share
ATX	Appendix 4C - quarterly - June 16 Qtr-IIL.AX	PRICE SENSITIVE	29/07/16	505.79KB	Share
ATX	Final Stage of Capital Raising Programme Completed-IIL.AX	PRICE SENSITIVE	20/07/16	258.66KB	Share
ATX	Rights Issue Booklet-IIL.AX	PRICE SENSITIVE	10/06/16	563.32KB	Share
ATX	Placement & Rights Issue to Raise Additional Working Capital-IIL.AX	PRICE SENSITIVE	10/06/16	276.88KB	Share
ATX	Preliminary Final Report - YE 31 March 2016-IIL.AX	PRICE SENSITIVE	31/05/16	68.31KB	Share
ATX	Appendix 4C - Statement of Cashflows March 2016 Qtr-IIL.AX	PRICE SENSITIVE	29/04/16	500.84KB	Share
ATX	Clinical Trial Fully Enrolled and Strong Interest-IIL.AX	PRICE SENSITIVE	13/04/16	252.77KB	Share
ATX	Appendix 4C - Dec 2015 Quarterly Cash Flow Report	PRICE SENSITIVE	29/01/16	528.87KB	Share
ATX	Half Yearly Report and Accounts	PRICE SENSITIVE	30/11/15	171.87KB	Share
ATX	Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr	PRICE SENSITIVE	30/10/15	443.98KB	Share
ATX	Compassionate Use Program Update	PRICE SENSITIVE	25/09/15	214.32KB	Share
ATX	Placement to Raise Additional Working Capital	PRICE SENSITIVE	21/09/15	198.78KB	Share
ATX	Trading Halt	PRICE SENSITIVE	17/09/15	384.05KB	Share
ATX	Appendix 4C - June 15 Qtr Cash Flow Report	PRICE SENSITIVE	30/07/15	442.01KB	Share
ATX	Preliminary Final Report - Year Ended 31 March 2015	PRICE SENSITIVE	28/05/15	163.28KB	Share
ATX	Compassionate Use Program Update	PRICE SENSITIVE	20/05/15	209.82KB	Share

ATX App 4E - Preliminary Final Report YE 31 March 2021
31/05/21	PRICE SENSITIVE	327.33KB	Share
ATX Proposed issue of Securities - ATX
04/05/21	PRICE SENSITIVE	25.57KB	Share
ATX Amplia Announces $3.8m Share Placement
04/05/21	PRICE SENSITIVE	113.35KB	Share
ATX Trading Halt
30/04/21	PRICE SENSITIVE	195.75KB	Share
ATX Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
28/04/21	PRICE SENSITIVE	181KB	Share
ATX Quarterly Report and Shareholder Update
28/04/21	PRICE SENSITIVE	2.21MB	Share
ATX ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
20/04/21	PRICE SENSITIVE	186.09KB	Share
ATX Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
15/04/21	PRICE SENSITIVE	103.52KB	Share
ATX Amplia and Garvan Institute Enter Collaboration Agreement
18/03/21	PRICE SENSITIVE	109.54KB	Share
ATX Amplia Completes Single Dose Study of AMP945
17/03/21	PRICE SENSITIVE	102.66KB	Share
ATX Amplia Initiates Multiple Dose Study of AMP945
17/02/21	PRICE SENSITIVE	105.52KB	Share
ATX Investor Update - February 2021
11/02/21	PRICE SENSITIVE	1.9MB	Share
ATX Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
28/01/21	PRICE SENSITIVE	246.63KB	Share
ATX Amplia Receives $0.53m R&D Tax Incentive
02/12/20	PRICE SENSITIVE	104.44KB	Share
ATX Appendix 4D and Financial Report Half Year Ended 30 Sep 2020
27/11/20	PRICE SENSITIVE	828.49KB	Share
ATX ATX - Sep 2020 Quarter Activities and Cashflow Reports
29/10/20	PRICE SENSITIVE	165.5KB	Share
ATX Response to ASX Price Query
20/10/20	PRICE SENSITIVE	205.56KB	Share
ATX First Human Dose in Phase 1 Clinical Trial of AMP945
08/10/20	PRICE SENSITIVE	105.87KB	Share
ATX Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial
08/09/20	PRICE SENSITIVE	108KB	Share
ATX Entitlement Offer Completed
30/07/20	PRICE SENSITIVE	106.98KB	Share
ATX Quarterly Activities and Cashflow Reports - June 2020
27/07/20	PRICE SENSITIVE	219.1KB	Share
ATX Nucleus Network Appointed to Conduct Phase 1 Clinical Trial
23/07/20	PRICE SENSITIVE	104.82KB	Share
ATX Institutional Entitlement Offer Completed
03/07/20	PRICE SENSITIVE	109.29KB	Share
ATX Capital Raising - Investor Presentation
01/07/20	PRICE SENSITIVE	3.63MB	Share
ATX Entitlement Offer to Fund Phase 1 Clinical Trial
01/07/20	PRICE SENSITIVE	226.49KB	Share
ATX Trading Halt
01/07/20	PRICE SENSITIVE	481.97KB	Share
ATX Pause in Trading
01/07/20	PRICE SENSITIVE	115.53KB	Share
ATX Preliminary Toxicology Studies Support Phase1 Clinical Trial
30/06/20	PRICE SENSITIVE	105.32KB	Share
ATX Trading Halt
29/06/20	PRICE SENSITIVE	134.89KB	Share
ATX Preliminary Final Report - YE 31 March 2020
29/05/20	PRICE SENSITIVE	226.35KB	Share
ATX FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
19/05/20	PRICE SENSITIVE	113.17KB	Share
ATX Quarterly Activities Report - March 2020 Qtr
28/04/20	PRICE SENSITIVE	114.28KB	Share
ATX App 4C - Quarterly Cash Flow Report - March 2020 Qtr
28/04/20	PRICE SENSITIVE	163.85KB	Share
ATX FDA Awards Orphan Drug Designation for Pancreatic Cancer
25/03/20	PRICE SENSITIVE	103.05KB	Share
ATX Dr. John Lambert appointed as Managing Director
06/02/20	PRICE SENSITIVE	100.02KB	Share
ATX Appendix 4C Cash Flow - Dec 2019 Qtr
30/01/20	PRICE SENSITIVE	179.52KB	Share
ATX Amplia Therapeutics Undertakes Placement
20/01/20	PRICE SENSITIVE	102.62KB	Share
ATX Trading Halt
16/01/20	PRICE SENSITIVE	180.43KB	Share
ATX App 4D - Financial Report Half Year Ended 30 Sep 2019
29/11/19	PRICE SENSITIVE	658.67KB	Share
ATX App 4C - Sep 2019 Qtr Cash Flows Statement
01/11/19	PRICE SENSITIVE	77.92KB	Share
ATX Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
31/07/19	PRICE SENSITIVE	191.95KB	Share
ATX RightsIssue Participation Supports Clinical-Enabling Studies
31/07/19	PRICE SENSITIVE	106.94KB	Share
ATX Amplia Therapeutics Reports Lead Candidate Preclinical Data
23/07/19	PRICE SENSITIVE	230.93KB	Share
ATX Rights Issue Prospectus
28/06/19	PRICE SENSITIVE	350.41KB	Share
ATX Dr John Lambert appointed as new CEO
24/06/19	PRICE SENSITIVE	116.58KB	Share
ATX Capital Raising for Clinical-Enabling Studies
12/06/19	PRICE SENSITIVE	104.96KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2019
29/05/19	PRICE SENSITIVE	141.78KB	Share
ATX Appendix 4C - Quarterly Statement of Cash Flows
30/04/19	PRICE SENSITIVE	162.91KB	Share
ATX European Patent Completes IP Protection in Major Markets
01/04/19	PRICE SENSITIVE	116.22KB	Share
ATX Appendix 4C - December 2018 Quarter Cashflow Statement
29/01/19	PRICE SENSITIVE	161.87KB	Share
ATX App 4D Half Year Accounts 30 Sep 2018
29/11/18	PRICE SENSITIVE	702.6KB	Share
ATX Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	213.29KB	Share
ATX Response to ASX Query
14/08/18	PRICE SENSITIVE	591.8KB	Share
ATX Appendix 4C - June 2018 Quarter Cashflow Statement
30/07/18	PRICE SENSITIVE	169.64KB	Share
ATX European Patent Granted for Innate's Drug Candidate AMP-886
23/07/18	PRICE SENSITIVE	121.4KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2018
31/05/18	PRICE SENSITIVE	756.28KB	Share
ATX App 4C - March 2018 Quarterly Cash Flow Report
30/04/18	PRICE SENSITIVE	158.74KB	Share
ATX Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates
23/03/18	PRICE SENSITIVE	224.03KB	Share
ATX S&P DJ Indices Announces March Quarterly Rebalance
09/03/18	PRICE SENSITIVE	201.26KB	Share
ATX Appendix 4C - December 2017 Quarter
31/01/18	PRICE SENSITIVE	648.21KB	Share
ATX Half Yearly Report and Accounts - HY ending 30 Sep 2017
30/11/17	PRICE SENSITIVE	1.22MB	Share
ATX Appendix 4C - September 2017 Quarter Cashflows
30/10/17	PRICE SENSITIVE	650.42KB	Share
ATX Corporate Update
20/10/17	PRICE SENSITIVE	480.31KB	Share
ATX App 4C - Quarterly Statement of Cashflows - June 2017 Qtr
28/07/17	PRICE SENSITIVE	647.2KB	Share
ATX No Change in Trial Outcome Following Additional Analysis
21/07/17	PRICE SENSITIVE	500.52KB	Share
ATX Response to ASX Price Query
11/07/17	PRICE SENSITIVE	169.59KB	Share
ATX Top-Line Results for Trial of MIS416
27/06/17	PRICE SENSITIVE	528.48KB	Share
ATX Trading Halt
23/06/17	PRICE SENSITIVE	326.24KB	Share
ATX FDA Clearance - MIS416 Investigational New Drug Application
21/06/17	PRICE SENSITIVE	368.33KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2017
31/05/17	PRICE SENSITIVE	252.45KB	Share
ATX Appendix 4C - March 17 Quarter Statement of Cash Flows
28/04/17	PRICE SENSITIVE	655.95KB	Share
ATX Completion of Phase 2B Trial of MIS416
20/04/17	PRICE SENSITIVE	383.67KB	Share
ATX Private Placement to raise Additional Working Capital
17/03/17	PRICE SENSITIVE	392.4KB	Share
ATX Trading Halt
16/03/17	PRICE SENSITIVE	618.44KB	Share
ATX S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
ATX Phase 2B Trial of MIS416 on Schedule to Complete April 2017
28/02/17	PRICE SENSITIVE	372.37KB	Share
ATX TOV: IIL Panel Declines to Conduct Proceedings
20/02/17	PRICE SENSITIVE	73.18KB	Share
ATX Appendix 4C - Dec 2016 Quarter Statement of Cashflows
31/01/17	PRICE SENSITIVE	654.86KB	Share
ATX Response to ASX Price Query
27/01/17	PRICE SENSITIVE	773.02KB	Share
ATX Response to Price Query
30/12/16	PRICE SENSITIVE	504.92KB	Share
ATX App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16
29/11/16	PRICE SENSITIVE	531.05KB	Share
ATX Phase 2B Update - Patients Wanting Access to Drug Post Trial
07/11/16	PRICE SENSITIVE	370.49KB	Share
ATX Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr-IIL.AX
31/10/16	PRICE SENSITIVE	668.82KB	Share
ATX Clinical Trials Update - 2016 Bioshares Biotech Summit-IIL.AX
02/08/16	PRICE SENSITIVE	1013.24KB	Share
ATX Appendix 4C - quarterly - June 16 Qtr-IIL.AX
29/07/16	PRICE SENSITIVE	505.79KB	Share
ATX Final Stage of Capital Raising Programme Completed-IIL.AX
20/07/16	PRICE SENSITIVE	258.66KB	Share
ATX Rights Issue Booklet-IIL.AX
10/06/16	PRICE SENSITIVE	563.32KB	Share
ATX Placement & Rights Issue to Raise Additional Working Capital-IIL.AX
10/06/16	PRICE SENSITIVE	276.88KB	Share
ATX Preliminary Final Report - YE 31 March 2016-IIL.AX
31/05/16	PRICE SENSITIVE	68.31KB	Share
ATX Appendix 4C - Statement of Cashflows March 2016 Qtr-IIL.AX
29/04/16	PRICE SENSITIVE	500.84KB	Share
ATX Clinical Trial Fully Enrolled and Strong Interest-IIL.AX
13/04/16	PRICE SENSITIVE	252.77KB	Share
ATX Appendix 4C - Dec 2015 Quarterly Cash Flow Report
29/01/16	PRICE SENSITIVE	528.87KB	Share
ATX Half Yearly Report and Accounts
30/11/15	PRICE SENSITIVE	171.87KB	Share
ATX Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr
30/10/15	PRICE SENSITIVE	443.98KB	Share
ATX Compassionate Use Program Update
25/09/15	PRICE SENSITIVE	214.32KB	Share
ATX Placement to Raise Additional Working Capital
21/09/15	PRICE SENSITIVE	198.78KB	Share
ATX Trading Halt
17/09/15	PRICE SENSITIVE	384.05KB	Share
ATX Appendix 4C - June 15 Qtr Cash Flow Report
30/07/15	PRICE SENSITIVE	442.01KB	Share
ATX Preliminary Final Report - Year Ended 31 March 2015
28/05/15	PRICE SENSITIVE	163.28KB	Share
ATX Compassionate Use Program Update
20/05/15	PRICE SENSITIVE	209.82KB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 18.5¢		Change -0.005(2.63%)		Mkt cap ! $89.99M

Open	High	Low	Value	Volume
18.5¢	19.0¢	18.0¢	$125.2K	677.4K

Buyers (Bids)

No.	Vol.	Price($)
21	678933	18.0¢

Sellers (Offers)

Price($)	Vol.	No.
18.5¢	20000	1

View Market Depth

No.	Vol.	Price($)
21	678933	0.180
23	671916	0.175
28	1213675	0.170
12	181247	0.165
11	367265	0.160

Price($)	Vol.	No.
0.185	155213	3
0.190	351658	15
0.195	582216	10
0.200	322669	7
0.205	290433	9

Last trade - 10.56am 13/08/2025 (20 minute delay)


Last 18.3¢		Change -0.005 ( 1.35 %)
Open	High	Low	Volume
18.5¢	18.5¢	18.0¢	303314
Last updated 11.00am 13/08/2025 ?

ATX (ASX) Chart

AMPLIA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available